VolitionRX landmark sepsis biomarker validation and commercial update
Landmark sepsis biomarker validation and commercial update spark VNRX premarket surge
- VolitionRx released two PRs on Aug 26 detailing peer-reviewed validation of Nu.Q NETs in Critical Care Medicine, showing it independently predicts 28-day mortality and renal replacement therapy need in sepsis patients.
- Corporate update highlighted 112% H1 2026 revenue growth to $1.4M, progress toward $5M vet milestone, Sysmex platform transfer, and active licensing talks with over a dozen global diagnostics firms.
- News targets ~$27B combined TAM across sepsis ($3.8B+), cancer, and vet pillars; includes upcoming $7.3M French DETECSEPS program starting Sept 2026.
- Stock saw extreme volatility on Aug 26 with 62M+ volume (vs ~1M avg), opening higher then closing down ~12% at $0.34 before strong after-hours recovery.
- Premarket gain on Aug 27 reflects continued retail/investor digestion of positive clinical and partnership data in this micro-cap epigenetics name.
- Prior recent news (Q2 earnings, finger-prick test data) built momentum, but Aug 26 releases served as the clear near-term trigger.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.